Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE STAVUDINE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE STAVUDINE NEVIRAPINE.
EMTRICITABINE vs LAMIVUDINE; STAVUDINE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with natural substrate and causing chain termination. Stavudine is an NRTI that inhibits HIV-1 reverse transcriptase after intracellular phosphorylation to its active triphosphate form. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet containing lamivudine 150 mg, stavudine 30 mg (or 40 mg if weight ≥60 kg), and nevirapine 200 mg orally twice daily.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: 5-7 h (prolonged in renal impairment); Stavudine: 1.6 h (prolonged in renal impairment, ~3.5-8 h in ESRD); Nevirapine: ~45 h (single dose), ~25-30 h (multiple doses due to autoinduction; prolonged in hepatic impairment).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: ~70% renal (glomerular filtration and tubular secretion), ~30% unchanged; Stavudine: ~40% renal (tubular secretion), ~60% metabolized to inactive metabolites; Nevirapine: ~80% renal (metabolites, <5% unchanged), ~10% fecal.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."